PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) shares dropped 1.8% on Tuesday . The company traded as low as $0.6740 and last traded at $0.69. Approximately 204,474 shares traded hands during trading, an increase of 2,215% from the average daily volume of 8,831 shares. The stock had previously closed at $0.7025.
PharmaCyte Biotech Stock Down 1.8%
The business’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.88.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Featured Articles
- Five stocks we like better than PharmaCyte Biotech
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Unlocked: Elon Musk’s Next Big IPO
- Elon Musk already made me a “wealthy man”
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
